B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells

Oncotarget

Volumn 5, Issue 24, 2014, Pages 12607-12620

  Roos, Wynand P ^a   Quiros, Steve ^a   Krumm, Andrea ^a   Merz, Stephanie ^a   Switzeny, Olivier Jérôme ^a   Christmann, Markus ^a   Loquai, Carmen ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

BRAF; Fotemustine; Melanoma; Temozolomide; Vemurafenib

Indexed keywords

B RAF KINASE; FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TEMOZOLOMIDE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; DACARBAZINE; INDOLE DERIVATIVE; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; METHYLATION; MGMT GENE; PROMOTER REGION; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; HUMANS; INDOLES; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84921328300     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2610     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108.
2. Eigentler TK, Caroli UM, Radny P and Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003; 4(12):748-759.
3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18(1):158-166.
4. Reid JM, Kuffel MJ, Miller JK, Rios R and Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999; 5(8):2192-2197.
5. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997; 23(1):35-61.
6. Fu D, Calvo JA and Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012; 12(2):104-120.
7. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M and Kaina B. Temozolomideand fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer. 2009; 100(2):322-333.
8. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ and Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer. 2007; 97(9):1225-1233.
9. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Christmann M and Kaina B. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomideinduced DNA damage. PLoS One. 2013; 8(1):e55665.
10. Tong WP, Kirk MC and Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl] ethane in DNA treated with N,N'-bis(2-chloroethyl)-Nnitrosourea. Cancer Res. 1982; 42(8):3102-3105.
11. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004; 22(6):1118-1125.
12. Falkson CI, Falkson G and Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs. 1994; 12(3):251-254.
13. Addeo R, Zappavigna S, Luce A, Facchini S and Caraglia M. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert opinion on drug safety. 2013; 12(5):729-740.
14. Kaina B, Christmann M, Naumann S and Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007; 6(8):1079-1099.
15. Kaina B, Fritz G, Mitra S and Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis. 1991; 12(10):1857-1867.
16. Chen JM, Zhang YP, Wang C, Sun Y, Fujimoto J and Ikenaga M. O6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis. 1992; 13(9):1503-1507.
17. Christmann M, Verbeek B, Roos WP and Kaina B. O(6)- Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 2011; 1816(2):179-190.
18. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP and Thatcher N. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998; 78(9):1199- 1202.
19. Roos WP, Jost E, Belohlavek C, Nagel G, Fritz G and Kaina B. Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN-{beta} and Valproic Acid. Cancer Res. 2011; 71(12):4150-4160.
20. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001; 409(6817):207-211.
21. Barckhausen C, Roos WP, Naumann SC and Kaina B. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53- triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene. 2014; 33(15):1964-1974.
22. Christmann M, Pick M, Lage H, Schadendorf D and Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer. 2001; 92(1):123-129.
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-954.
24. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105(8):3041-3046.
25. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
26. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18(6):683-695.
27. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS and Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther. 2005; 4(9):1303-1310.
28. Park SJ, Hong SW, Moon JH, Jin DH, Kim JS, Lee CK, Kim KP, Hong YS, Choi EK, Lee JS, Lee JL and Kim TW. The MEK1/2 Inhibitor AS703026 Circumvents Resistance to the BRAF Inhibitor PLX4032 in Human Malignant Melanoma Cells. Am J Med Sci. 2013; 346(6):494-498.
29. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest. 2013; 123(5):2257-2267.
30. Gaddameedhi S, Kemp MG, Reardon JT, Shields JM, Smith-Roe SL, Kaufmann WK and Sancar A. Similar nucleotide excision repair capacity in melanocytes and melanoma cells. Cancer Res. 2010; 70(12):4922-4930.
31. Norregaard A, Jensen SS, Kolenda J, Aaberg-Jessen C, Christensen KG, Jensen PH, Schroder HD and Kristensen BW. Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. Neurotox Res. 2012; 22(1):43-58.
32. Nikolova T, Hennekes F, Bhatti A and Kaina B. Chloroethylnitrosourea-induced cell death and genotoxicity: cell cycle dependence and the role of DNA double-strand breaks, HR and NHEJ. Cell Cycle. 2012; 11(14):2606- 2619.
33. Roos W, Baumgartner M and Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/ CD95/Apo-1. Oncogene. 2004; 23(2):359-367.
34. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D and Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-2147.
35. Quereux G and Dreno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother. 2011; 12(18):2891- 2904.
36. Rapp UR, Gotz R and Albert S. BuCy RAFs drive cells into MEK addiction. Cancer Cell. 2006; 9(1):9-12.
37. Heinzerling L, Baiter M, Kuhnapfel S, Schuler G, Keikavoussi P, Agaimy A, Kiesewetter F, Hartmann A and Schneider-Stock R. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer. 2013; 109(11):2833-2841.
38. Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schlappi M, Moch H and von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep. 2012; 28(2):654-658.
39. Lyons AB and Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994; 171(1):131-137.
40. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 1976; 72:248-254.
41. Preuss I, Eberhagen I, Haas S, Eibl RH, Kaufmann M, von Minckwitz G and Kaina B. O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer. 1995; 61(3):321-326.
42. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC and Kretzschmar HA. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer. 2007; 121(11):2458-2464.
43. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19):1350-1354.
44. Furst RW, Meyer HH, Schweizer G and Ulbrich SE. Is DNA methylation an epigenetic contribution to transcriptional regulation of the bovine endometrium during the estrous cycle and early pregnancy?. Mol Cell Endocrinol. 2012; 348(1):67-77.
45. Graf F, Fahrer J, Maus S, Morgenstern A, Bruchertseifer F, Venkatachalam S, Fottner C, Weber MM, Huelsenbeck J, Schreckenberger M, Kaina B and Miederer M. DNA double strand breaks as predictor of efficacy of the alphaparticle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One. 2014; 9(2):e88239.